Amanda is Erasca’s Vice President of Portfolio and Program Leadership and has been with the Company since its inception in 2018. She brings more than 15 years of program leadership and project management experience in the biotechnology and pharmaceutical industries, with much of this time focused on driving oncology assets through all stages of the drug development process, ranging from pre-IND through post-marketing activities. Prior to joining Erasca, Amanda was a Program Team Leader at Ignyta, where she helped drive a pre-IND asset into Phase 1 clinical development and supported the advancement of Rozlytrek® through the registration-enabling phase of clinical development. Before Ignyta, she was the Portfolio Director at MEI Pharma, a late-stage pharmaceutical company focused on developing potential new therapies for cancer. Amanda also held project management positions at Pfizer, Inc., where she helped progress both early- and late-stage oncology assets, including Sutent® and Xalkori®, through clinical development and post-marketing activities. Earlier in her career, Amanda worked in oncology research as a postdoctoral fellow at the University of California, San Francisco, focusing on the characterization of a novel drug delivery system for anti-angiogenic cancer therapeutics.
Amanda earned a Ph.D. in Pharmacology and MBA from the Pennsylvania State University, and a B.S. in Chemistry from the University of Kentucky.